Brazil Case Study Finds 5-Gram Psilocybin Dose Temporarily Restored Functions in Alzheimer's Patient
Updated
Updated · ScienceAlert · Jun 8
Brazil Case Study Finds 5-Gram Psilocybin Dose Temporarily Restored Functions in Alzheimer's Patient
1 articles · Updated · ScienceAlert · Jun 8
Summary
An Alzheimer’s patient in her 80s regained speech, bladder control and some independence for several weeks after a supervised 5-gram psilocybin mushroom dose in Brazil, according to a case report in Frontiers in Neuroscience.
Roughly 19 hours after the first dose, she began speaking to herself for hours; over the following days, researchers said she could dress and walk by herself, hold eye contact and engage in conversation.
A second supervised 3-gram dose a month later reportedly left her verbally expressive throughout, with improved facial expression, humor and gait, including describing emotional scenes unprompted.
The authors said the report does not show reversal of Alzheimer’s pathology and lacked brain monitoring and standardized cognitive testing, framing it as hypothesis-generating rather than proof of efficacy.
The case adds to early psilocybin research in older adults, but future randomized trials will need to determine whether the drug can safely improve symptoms in mild cognitive impairment or Alzheimer’s disease.
Beyond Alzheimer's, could psychedelics become the key to reversing brain aging and enhancing cognitive health for everyone?
If psilocybin can 'reawaken' a damaged brain, could non-hallucinogenic versions offer a safer, permanent fix for dementia?
Temporary Restoration of Function in Advanced Alzheimer’s: The 2026 Brazil Psilocybin Case and Its Implications for Dementia Care
Overview
A groundbreaking case report from Brazil described an elderly woman with advanced Alzheimer's who, after receiving a supervised dose of psilocybin-containing mushrooms, showed temporary but remarkable improvements in speech, memory, continence, and mobility. These gains, observed about 19 hours after treatment, lasted several weeks before fading. The report suggests that psilocybin may temporarily unlock latent brain functions, possibly by promoting neuroplasticity and neurogenesis, but emphasizes that these effects are not a cure and remain speculative. The findings highlight the need for further controlled studies to explore whether such transient improvements can be reliably achieved and understood.